+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

PEGylated Protein Therapeutics Market by Product Type, By Application By Sales Channel - Global Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4621203
  • Report
  • Region: Global
  • 166 pages
  • Allied Analytics LLP
1 of 4
PEGylation refers to the process of amalgamation or attachment of polyethylene glycol (PEG) polymer chains with macromolecules, such as drug molecule, therapeutic protein, or vesicles by covalent bonding. PEGylation offers several advantages, such as improved drug solubility, reduced dosage frequency, and increased drug stability, which boost its demand in the market.

The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9% from 2018 to 2025. The factors that propel the PEGylated protein therapeutics market growth include high prevalence of chronic diseases, such as cancer, kidney diseases, and rheumatoid arthritis. In addition, growth in the biologics sector with an increase in R&D expenditure of pharmaceutical and biopharmaceutical companies boosts the market. Furthermore, increase in government funding and grants for research activities enhance opportunities for the growth of the market. However, high price, and expected launch of generic drugs can hinder the growth.

The global PEGylated protein therapeutics market is segmented based on product type, application, sales channel, and region. According to the product type, the market is classified into colony stimulating factor, interferon, erythropoietin, recombinant factor VIII, monoclonal antibody, enzyme, and others. Based on application, the market is categorized into cancer, autoimmune disease, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorder, and others. According to the sales channel, it is segmented into hospital pharmacy, online provider, and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key players profiled in the report include Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Product Type

Colony Stimulating Factor
Interferon
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibody
Enzyme
Others

By Application Type

Cancer
Autoimmune Disease
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorder
Others

By Sales Channel

Hospital Pharmacy
Online Provider
Retail Pharmacy

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Amgen Inc.
AstraZeneca PLC
Biogen, Inc.
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,),
Horizon Pharma plc.
Leadiant Biosciences S.p.A.
Merck & Co., Inc. (Schering-Plough Corporation)
Pfizer Inc.
Shire plc (Baxalta)
UCB S.A.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of key players profiled in the report
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key Findings of the Study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.3. Top Player Positioning, 2017
3.4. Clinical Trials
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Strong presence of pipeline drugs
3.5.1.2. Advantages offered by PEGylation
3.5.1.3. Rise in the prevalence of chronic diseases
3.5.2. Restraints
3.5.2.1. High costs associated with drug development
3.5.2.2. Expected Launch of generic drugs
3.5.3. Opportunities
3.5.3.1. Untapped emerging economies
3.5.3.2. Growth in adoption of PEGylated protein therapeutics
3.5.4. Impact Analyses

CHAPTER 4: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Colony Stimulating Factor
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3. Interferon
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. Erythropoietin (EPO)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.5. Recombinant Factor VIII
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.6. Monoclonal Antibody
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.7. Enzyme
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast
4.8. Other PEGylated Protein Therapeutics
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast

CHAPTER 5: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Market size and forecast
5.3. Autoimmune Disease
5.3.1. Market size and forecast
5.4. Hepatitis
5.4.1. Market size and forecast
5.5. Multiple Sclerosis
5.5.1. Market size and forecast
5.6. Hemophilia
5.6.1. Market size and forecast
5.7. Gastrointestinal Disorders
5.7.1. Market size and forecast
5.8. Other Applications
5.8.1. Market size and forecast

CHAPTER 6: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY SALES CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Market size and forecast, by region
6.3. Online Providers
6.3.1. Market size and forecast, by region
6.4. Retail Pharmacy
6.4.1. Market size and forecast, by region

CHAPTER 7: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America market size and forecast, by country
7.2.2.1. U.S.
7.2.2.2. Rest of North America
7.2.3. North America market size and forecast, by product type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by sales channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe market size and forecast, by country
7.3.2.1. Germany
7.3.2.2. France
7.3.2.3. UK
7.3.2.4. Rest of Europe
7.3.3. Europe market size and forecast, by product type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by sales channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific market size and forecast, by country
7.4.2.1. Japan
7.4.2.2. China
7.4.2.3. India
7.4.2.4. Rest of Asia-Pacific
7.4.3. Asia-Pacific market size and forecast, by product type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by sales channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by country
7.5.2.1. Brazil
7.5.2.2. Rest of LAMEA
7.5.3. LAMEA market size and forecast, by product type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by sales channel

CHAPTER 8: COMPANY PROFILES
8.1. Amgen Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. AstraZeneca PLC
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Biogen Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Horizon Pharma plc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product Portfolio
8.5.5. Business performance
8.6. Leadiant Biosciences S.p.A.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product Portfolio
8.7. Merck & Co., Inc. (Schering-Plough Corporation)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Pfizer Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. Shire plc (Baxalta)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. UCB S.A.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product Portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, " PEGylated Protein Therapeutics Market by Product Type, Application, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market was valued at $10,388 million in 2017, and is projected to reach $17,813 million by 2025, growing at a CAGR of 6.9% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.

The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.

By product type, the colony stimulating factor segment accounted for nearly half share of the global occupational medicine market in 2017. Furthermore, the cancer segment is anticipated to grow at the highest rate of 7.4% during the forecast period.

Key Findings of the PEGylated Protein Therapeutics Market:

North America occupied nearly two-thirds share of the global PEGylated protein therapeutics market in 2017
The cancer segment is anticipated to grow with the highest CAGR throughout the forecast period.
Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

North America was the leading revenue contributor to the global market in 2017, owing to FDA approval and launch of new drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR of 7.4% from 2018 to 2025, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward chronic disorders.

The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll